Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.24.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock, Common [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 2,774 $ 1,347 $ 205,964,847 $ (182,547,265) $ 253,734 $ (5,281,180) $ 18,394,257
Beginning balance, shares at Dec. 31, 2021 2,774,394 1,346,661          
Issuance of common stock in connection with purchase of in-process research and development 173 1,293,577 1,293,750
Issuance of common stock in connection with purchase of in-process research and development, shares   172,500          
Exercise of purchase warrants
Exercise of purchase warrants, shares   199          
Share-based expense 511,480 511,480
Net loss (6,552,353) (6,552,353)
Ending balance, value at Dec. 31, 2022 $ 2,774 $ 1,520 207,769,904 (189,099,618) 253,734 (5,281,180) 13,647,134
Ending balance, shares at Dec. 31, 2022 2,774,394 1,519,360          
Issuance of common stock to adjust for reverse split rounding $ 16 (16)
Issuance of common stock to adjust for reverse split rounding, shares   15,941          
Conversion of Series A preferred stock to shares of common stock $ (970) $ 8 962
Conversion of Series A preferred stock to shares of common stock, shares (970,000) 8,084          
Issuance of common stock in connection with purchase of in-process research and development, shares   15,941          
Share-based expense 283,085 283,085
Net loss (4,134,578) (4,134,578)
Ending balance, value at Dec. 31, 2023 $ 1,804 $ 1,544 $ 208,053,935 $ (193,234,196) $ 253,734 $ (5,281,180) $ 9,795,641
Ending balance, shares at Dec. 31, 2023 1,804,394 1,543,385